Active Radiopharmaceutical Developers

Develops peptide-targeted radionuclide therapeutics and FAP-targeting radioligands primarily through out-licensing to larger partners

Berlin, Germany

Shanghai-listed biopharma (688435.SH) with RDC/radioligand pipeline including Lu-177-PSMA-3D1015 in clinical development for metastatic castration-resistant prostate cancer; primarily an ADC and immuno-oncology company expanding into radiopharmaceuticals

Shanghai, China

Early-stage developer of targeted radiopharmaceuticals with α- and β-nuclide programs; eight in-research pipelines including pan-solid-tumor programs

Hangzhou, China

Engineers precision radiopharmaceuticals using its ROVEr™ antibody engineering platform to deliver alpha (Ac-225) or beta emitters against novel targets

South San Francisco, CA, USA

GPC-3-targeted radioligand therapy for hepatocellular carcinoma (HCC) using novel peptide drug candidates; collaboration with BMS/PeptiDream

Shanghai / Greater China, China

Develops anti-L1CAM monoclonal antibody radioconjugates for paediatric and adult solid tumours, including radiolabeled OTLC anti-L1CAM antibodies; spin-out from UCLouvain collaborating with SCK CEN on therapeutic radionuclide conjugation

Brussels, Belgium

Clinical-stage biopharma developing 18F-ACI-12589, the first-ever alpha-synuclein PET tracer with first-in-human data published in Nature Communications; wholly owned diagnostic for MSA, Parkinson's disease and other synucleinopathies

Lausanne, Switzerland

Commercial oncology company holding US Zevalin radioimmunotherapy rights

East Windsor, NJ, USA

NYSE-listed company with a novel preclinical Ac-225 solid-tumor program (ATNM-400) targeting a non-PSMA antigen in prostate, NSCLC, and breast cancer

New York, NY, USA

Precision radiopharmaceutical biotech translating covalent medicinal chemistry into next-generation radioligand therapies, with an isotope-agnostic approach

Cambridge, MA (co-HQ Oslo, Norway), USA/Norway

Theranostic radiopharmaceutical developer with pipeline including AIP-201, AIP-105 (rare paediatric), AIP-301, and AIP-102 across oncology, infectious disease and rare disease; holds first accelerator-produced Ac-225 patent; also provides CRO services

Boynton Beach, FL, USA

Lead-212 targeted alpha therapy developer

Melbourne, Australia

Affibody molecule platform company developing HER2 radioligand therapy

Stockholm, Sweden

Develops CD44v6-targeting radioimmunotherapy (177Lu-AKIR001) for solid tumors including head & neck and thyroid cancers; FIH Phase 1 initiated

Uppsala, Sweden

Miniprotein Ac-225 radioconjugate developer for solid tumors

Boston, MA, USA

Develops At-211-based Targeted Alpha Therapy (TAT) radiopharmaceuticals across multiple cancer indications

Osaka, Japan

MC1R-targeted radiopharmaceutical developer for melanoma and other cancers

Vancouver, BC / Boston, MA, Canada / USA

Develops next-generation Pb-212 alpha radioligand therapies using proprietary AlphaDirect Pb-212 generator technology

Shanghai, China

Clinical-stage developer of Re-188-P2045 (Tozaride), a SSTR2-targeting peptide radiotherapy for neuroendocrine tumours and lung cancer, paired with 99mTc-P2045 diagnostic imaging agent; advancing through Phase 2

Somerville, MA, USA

Clinical-stage company developing tau-targeted PET diagnostic tracers (18F-APN-1607/florzolotau) and therapeutic radiopharmaceuticals for neurodegenerative diseases and brain cancers; Phase 2/3 tau PET imaging studies ongoing globally

Taipei / Suzhou, Taiwan / China

RPT company developing PSMA and other targeted radioconjugates

Madison, WI, USA

SSTR2 antagonist and PARP-targeted radiopharmaceutical developer

Berlin, Germany

Lead-212 alpha radioligand therapy developer using AlphaDirect isotope isolation

Cambridge, MA, USA

Large pharma alpha-radioconjugate platform targeting PSMA, IGF-1R, EGFR/cMET and NTSR1

Cambridge / Hamilton, ON, UK / Canada

At-211 antibody-conjugate (girentuximab × CA-IX) for non-muscle-invasive bladder cancer; FIH Phase 1 PERSEVERANCE EU trial authorized

Saint-Herblain (Nantes), France

Commercial alpha-emitter franchise and next-generation Ac-225 oncology pipeline

Leverkusen, Germany

Chinese radionuclide therapeutic developer for bone metastases

Beijing, China

Develops Bicycle® Radioconjugates (BRC®) using proprietary bicyclic peptides carrying ²¹²Pb (alpha) for targeted radionuclide therapy

Cambridge, UK

Shanghai-listed biopharma (688506.SH) expanding into radiopharmaceuticals with BL-ARC001 (Lu-177 RDC) in clinical development for prostate cancer; primarily known as a leading Chinese ADC developer with BMS partnership on cadonilimab-equivalent

Chengdu, China

Chinese PSMA-targeted radioligand therapy developer

Shanghai / Nanjing, China

Develops an alpha-emitting radiohybrid PSMA-targeted therapeutic radiopharmaceutical (²²⁵Ac-rhPSMA-10.1) for prostate cancer

Oxford, UK

Academic spin-out (WuXi AppTec + Peking University Molecular Engineering) developing first-in-class covalent targeted radioligand therapies

Suzhou, China

Large pharma actinium-225 radiopharmaceutical platform via RayzeBio acquisition

Princeton, NJ / San Diego, CA, USA

Korean developer of fluorine-18 PET imaging agents including 18F-FP-CIT for Parkinson's disease diagnosis and novel oncology tracers; holds KFDA approvals for multiple diagnostic radiopharmaceuticals

Seoul, South Korea

Chengdu-based CRDMO with own therapeutic pipeline: TRC003, a PSMA-targeted radioligand in Phase 1/2 for metastatic castration-resistant prostate cancer (NCT07567521, 90 patients, sites in China); alpha-emitting RDC programs

Chengdu, China

PSMA-targeted theranostic developer: CTT1403 (177Lu radiotherapeutic, albumin-binding, Phase 1 complete at UCSF) paired with CTT1057 (18F PET diagnostic, Phase 1 complete); irreversible PSMA binding scaffold

Woodinville, WA, USA

Korean PSMA radioligand developer

Seoul, South Korea

Clinical-stage company with a phospholipid ether (PLE) platform; CLR 125 (Auger/I-125) in Phase 1b TNBC and CLR 225, an Ac-225 alpha emitter

Florham Park, NJ, USA

China domestic radioimmunotherapy manufacturer for hepatocellular carcinoma

Chengdu, China

Copper-64/copper-67 SAR theranostic radiopharmaceutical developer

Sydney, Australia

PSMA-targeted alpha radioantibody developer

Cambridge, MA, USA

Develops fluorescence-guided surgery and targeted radiopharmaceutical agents combining near-infrared fluorescent imaging with radioligand delivery for intraoperative tumour detection and treatment

Marlborough, MA, USA

uPAR-targeted theranostics company developing uTREAT radiopharmaceutical therapy

Copenhagen, Denmark

Large nuclear medicine company with approved legacy therapies and Phase 3 PSMA therapy

Paris, France

Granzyme B-targeted theranostic developer: CSB-321 PET diagnostic (Phase 1, validated in melanoma and NSCLC) paired with CSB-421 radiotherapeutic; Lantheus holds an option deal (March 2025) on the platform

Boston, MA, USA

Swiss biopharma developing terbium-161-based radioligand therapies for cancer through its Nucleo-Oncology programme; partners with Paul Scherrer Institute and CERN/ISOLDE for Tb-161 production; advancing proprietary theranostic candidates

Lausanne, Switzerland

Canadian biotech (CSE: DTC) developing Accum-enhanced radio-immunoconjugates in collaboration with Canadian Nuclear Laboratories using Ac-225 and In-111 isotopes; radiopharmaceuticals are a top development priority alongside its ADC programme

Montreal, Canada

Develops h11B6, a humanised monoclonal antibody targeting hK2 (human kallikrein 2) as a radioimmunotherapy carrier for prostate cancer; paired diagnostic and therapeutic applications using different radionuclide payloads

Lund, Sweden

Korean pharmaceutical company holding an approved Ho-166 locoregional radiotherapy product

Seoul, South Korea

Korea's leading radiopharmaceutical manufacturer with ~80% of the domestic FDG market; approved diagnostics (68Ga-PSMA-11, 18F-FES for breast cancer) and expanding into therapeutic radioligands and CDMO services

Seoul, South Korea

Large pharma radiopharmaceutical division with POINT-origin Lu-177 and Ac-225 assets plus new collaborations

Indianapolis, IN, USA

Radiopharma CDMO and proprietary developer; built a GMP facility in NJ; lead diagnostic OCTEVY (EVG321, CCK2-targeting, SCLC) in Phase II

Springfield, NJ, USA

Develops 99mTc-H7ND, a world-first FAP-targeted SPECT/CT diagnostic radiopharmaceutical (Class 1 innovative drug); CDE clinical trial approval December 2023; Phase 1 initiated April 2024 at Fudan Zhongshan Hospital; strategic collaboration with HTA/Atom HighTech

Jiaxing, China

Chinese developer and manufacturer of Sm-153-EDTMP (samarium-153 lexidronam) and other therapeutic radiopharmaceuticals for bone pain palliation in metastatic cancer; one of China's established radiopharmaceutical producers

Foshan / Beijing, China

Japan marketing authorization holder/commercial partner for Lutathera PRRT

Tokyo, Japan

Radionuclide drug conjugate (RDC) developer with global R&D operations spanning China, Belgium, and Germany; more than 30% of staff based in Belgium; developing nanoparticle-based radioligand therapies for solid tumours

Beijing, China

Fully integrated radiotherapeutics company with an Ac-225 lead program in Phase I and multiple preclinical programs (SSTR2, c-MET, B7H3) in discovery

Suzhou / Shanghai, China (global)

Developing alpha-emitter radiopharmaceuticals alongside beta-emitter programs for prostate and other cancers

Seoul, South Korea

Developer of novel FAPI (fibroblast activation protein inhibitor) radioligands for theranostic cancer applications; advancing FAP-targeted imaging and therapeutic agents through clinical development

San Diego, CA, USA

Develops glypican-1 (GPC1)-targeted radioimmunotherapy for pancreatic and other GPC1-expressing cancers; lead programme uses radiolabeled anti-GPC1 antibodies with Lu-177 and other therapeutic radionuclides

Sydney, Australia

HK-listed biopharma with early own-pipeline radiopharma programs; GPN01530 (diagnostic FAP RDC, FIH just starting for diagnostic use)

Wuhan / Chengdu, China

Pioneer of dual-target radiopharmaceuticals simultaneously targeting integrin αvβ3 and CD13 receptor; first-in-class theranostic RDC platform

Chongqing / Beijing / Suzhou, China

Major Chinese radiopharmaceutical developer and manufacturer under CNNC/CIRC with own clinical pipeline: F-18 Florastamin (Phase 3, prostate), Ga-68 DOTATATE (Phase 3, NETs), Lu-177 oxodotreotide (GEP-NETs); FutureChem collaboration on FC705 Lu-177 PSMA therapy; nationwide production and distribution network

Beijing, China

Develops CD8-targeted ImmunoPET imaging agents (89Zr-Df-IAB22M2C/tozarotide) to visualise immune-cell infiltration in tumours; partnered with Bristol Myers Squibb and Roche for clinical imaging trials; lead agent in Phase 2

Inglewood, CA, USA

Oncology biotech adding FAP-targeted radioligand therapy to its antibody and ADC pipeline; also advancing radiolabeled antibody programmes

Bothell, WA, USA

Munich-based early-stage company developing next-generation PET tracers for immune-response imaging and future radioligand therapies targeting cancer; backed by the EXIST Transfer of Research programme and Technical University of Munich

Munich, Germany

Novel PSAt-Ga radiolabeling technology (in-licensed from Theranostic Solutions, Copenhagen) allowing At-211, 131I, or 68Ga labeling

Switzerland, Switzerland

Vertically integrated radiopharma biotech with a late-clinical lead (ITM-11, Phase 3/NDA pending) and early-stage novel programs

Garching / Munich, Germany

Major Chinese pharma (SHA: 600276) with emerging radioligand therapy pipeline; developing proprietary RDC candidates including PSMA- and FAP-targeted radioligands; leveraging established oncology and clinical-trial infrastructure

Lianyungang, China

Chinese developer of JH020002, a Lu-177 radioligand therapy for advanced prostate cancer currently in clinical trials (also registered under Bivision Pharmaceuticals in the US); early-stage RDC pipeline

China

Large pharma with two Ac-225 prostate cancer radiopharmaceutical programmes

New Brunswick, NJ, USA

Large Indian pharma group with a proprietary radiopharma therapeutic pipeline including FAPI tracers in preclinical development and I-131 mIBG

Noida, India

Nuclear medicine company manufacturing and commercializing diagnostic and therapeutic radiopharmaceuticals

Kirkland, QC / Noida, Canada / India

Large-cap ADC company expanding into RDC; SKB107 (small-molecule RDC for bone metastases) is its first RDC program in Phase I as of Aug 2025

Chengdu (Sichuan), China

Radiopharmaceutical spin-out from Dongcheng (largest listed radiopharmaceutical company); Lu-177 PSMA in Phase II; FAP-targeted LNC1009 program

Yantai (Shandong), China

Commercial radiopharmaceutical company with legacy approved therapy and emerging therapeutic pipeline

North Billerica, MA, USA

Develops and commercialises molecular imaging agents for neurological diseases; portfolio includes Neuraceq (18F-florbetaben) for amyloid PET imaging in Alzheimer's disease diagnostics; expanding into tau and other neurodegenerative targets

Berlin, Germany

Builds a Cu-64 drug discovery platform for theranostic radiopharmaceuticals targeting cancers with unmet need

Chiba, Japan

Dresden-based radiopharmacy network company and research partner in SNRT (Saxon Network for Radionuclide Theranostics) developing dual-modality radiotheranostics

Dresden, Germany

Developer of 177Lu-oxodotreotide injection (SSTR2-targeted) for GEP-NETs; Phase III clinical trial with first patient dosed August 2025; C-Ray Therapeutics as exclusive CRDMO partner

Suzhou, China

Develops PET radiotracers for neuroinflammation and neurodegenerative diseases using proprietary 18F-labelled TSPO (translocator protein) ligands; advancing clinical imaging agents for brain inflammation detection

Copenhagen, Denmark

Chinese radiopharmaceutical developer with proprietary RDC pipeline targeting PSMA, FAP and other tumour antigens; building integrated development and manufacturing capabilities for radioligand therapies

Shanghai, China

Develops 225Ac-MTI-201, an MC1R-targeted alpha therapy in Phase 1 for metastatic uveal melanoma; also advancing MTI-301 and other MC1R-directed radioligands for melanoma and solid tumours; West Virginia University spinout

Morgantown, WV, USA

Develops DARPin-based targeted alpha therapies using Pb-212, co-developing 10 programs with Orano Med (MP0712 DLL3→SCLC now FIH 2025)

Zurich-Schlieren, Switzerland

Small privately held biotech developing Evans-blue-enhanced (albumin-binding) radiotherapeutics; lead EBTATE (Lu-177) with long-acting SSTR2 targeting

West Chester, PA, USA

uPAR-targeted antibody radioconjugate developer

Wilmette, IL, USA

ADC/RDC dual-track biotech using BioLattix platform; flagship radiopharma asset RT01 is a tissue-factor-targeting theranostic RDC (Zr-89/Lu-177/Ac-225) that dosed first patient in IIT February 2026; also developing bispecific RDC pipeline

Shanxi, China

Radiopharmaceutical nanoparticle company developing Ho-166 nanocarriers (XLNT-1) for targeted intraperitoneal delivery to ovarian cancer metastases

Storrs, CT, USA

Develops camelid single-domain antibody (sdAb/nanobody) radiopharmaceuticals as theranostic pairs for cancer precision medicine (imaging + therapy)

Borehamwood, Hertfordshire, UK

NYSE-listed (NAVB) developer of Tc-99m tilmanocept (Lymphoseek), an FDA-approved CD206-targeted radiopharmaceutical for sentinel lymph node mapping in cancer surgery; expanding into CD206-targeted immunodiagnostics

Dublin, OH, USA

Develops Affilin®-scaffold radiotheranostics for cancer; GAIASO focuses specifically on female cancers (ovarian, cervical, breast)

Halle (Saale) (Navigo); Germany/Australia (GAIASO), Germany

Full value-chain radiopharma developer; Y-90 microspheres advanced clinical, but FAP-targeted 177Lu-NRT6020 is a genuinely early theranostic asset

Chengdu, China

Leading Japanese radiopharmaceutical developer (Sumitomo Chemical / GE HealthCare JV); proprietary alphaSTARTZ platform: NMK89 (Zr-89 MUC5AC PET, FDA IND, FIH completed at BAMF Health) paired with NMT25 (Ac-225 therapeutic) for pancreatic cancer

Tokyo, Japan

Preclinical radiopharmaceutical company developing first-in-class targeted alpha therapies for liver cancer and metastatic indications

Oslo, Norway

Develops Betalutin (177Lu-lilotomab satetraxetan), a CD37-targeted antibody-radionuclide conjugate for non-Hodgkin lymphoma; Phase 2b PARADIGME trial ongoing; Oslo-listed clinical-stage radioimmunotherapy company

Oslo, Norway

Develops RDC therapeutics with global IND filings: 177Lu-NYM032 in Phase I/II (enrolment complete) for renal cancer; additional renal and solid-tumour programmes; 5 FDA and 5 NMPA INDs accepted; dual US-China operations

China / USA

Global radioligand therapy leader with approved Lu-177 products and next-generation alpha/beta pipeline

Basel, Switzerland

Scalable 18F-SSTR-PET radiotracer platform (FETO tracer) to address the 50% supply shortage of SSTR diagnostics for neuroendocrine tumours

London (Imperial College White City), UK

Develops ALDH1A1-targeted radiotheranostics using Lu-177/Ga-68 to detect and eliminate therapy-resistant cancers

London, UK

Develops copper-based (Cu-61/Cu-67) theranostic radiopharmaceuticals targeting PSMA, SSTR2, and FAP for solid tumour oncology

Basel / Munich, Switzerland / Germany

R&D spinout developing targeted alpha/beta radioligand therapies for hematological cancers (lymphoma, leukemia) using Th-228-derived isotopes

Oslo, Norway

Clinical-stage theranostic radiopharmaceutical company developing NV-VPAC1, a VPAC1 receptor-targeted platform pairing Cu-64 (PET diagnostic) with Cu-67 (therapeutic) for prostate, bladder, breast and other cancers

Park City, UT, USA

Biopharma developing radioligand therapy via the Promethe® platform using Affilin® vectors (collaboration with Navigo Proteins)

Dijon, France

Develops Radspherin, an alpha-emitting Ra-224-loaded calcium carbonate microparticle for intraperitoneal treatment of peritoneal carcinomatosis from ovarian and colorectal cancers; Phase 2 trials ongoing in Europe

Oslo, Norway

Develops FAP-targeted radioligands and small-molecule drug conjugates for solid tumours; proprietary FAP-binding scaffolds designed for improved tumour retention and theranostic pairing with diagnostic and therapeutic radionuclides

Vienna, Austria

TSE: 4564; develops OTSA101, an anti-FZD10 monoclonal antibody radioimmunotherapy (90Y/225Ac-labeled) for synovial sarcoma; first-in-human Synfrizz trial conducted; University of Tokyo spinout with oncology peptide vaccine platform

Kawasaki, Japan

Lead-212 targeted alpha therapy developer and manufacturer

Paris / Bessines-sur-Gartempe, France

Discovers, develops, and commercializes peptide-based radiopharmaceuticals (RI-PDC) across multiple oncology targets using PeptiDream's PDPS platform

Tokyo, Japan

Clinical-stage and early-stage developer of CXCR4-targeted radiopharmaceuticals (PentixaTher/PentixaFor) and novel preclinical radionuclide-therapy programs

Berlin / Würzburg, Germany

Develops radiolabeled antibodies including PPMX-T002 (anti-CDH3 / P-cadherin) repositioned for 225Ac alpha radioimmunotherapy; University of Tokyo spinout with diagnostic radiopharmaceutical and antibody platform programmes

Tokyo, Japan

Pb-212 alpha therapy developer with generator platform and theranostic imaging pairs

Seattle, WA / Coralville, IA, USA

Develops FAP-targeting radioligand therapies (OncoFAP platform, 177Lu-OncoFAP-23) for solid tumors; Phase 1 trial (Theratri, NCT06640413) ongoing

Siena, Italy (Philogen); Otelfingen (Zurich), Switzerland (Philochem), Italy / Switzerland

Preclinical radiopharmaceutical company focused on selectively targeting cancer cells and enabling deep tumor penetration

Bay Area, CA (inferred; HQ not publicly disclosed), USA

Developer of locally delivered rhenium-186 nanoliposome radiotherapeutics for CNS cancers

Austin, TX, USA

Nanobody/VHH radiopharmaceutical company targeting HER2 and FAP

Brussels, Belgium

Pretargeted radioligand therapy (RLT) platform using monoclonal antibodies (mAbs) as targeting vectors for alpha-emitting payloads.

Copenhagen, Denmark

Develops next-generation radioligand theranostics (RLT) targeting PSMA, FOLH1, and other tumor markers for solid cancers

Taipei, Taiwan

Holder of legacy Sr-89 bone-palliation radiopharmaceutical brand lineage

New York / Chicago, USA

Developer of CycloSam (Sm-153-DOTMP), a bone-targeting radiopharmaceutical for primary and metastatic bone cancers; FDA IND cleared; Telix Pharmaceuticals signed acquisition term sheet and $2M option fee (Nov 2023)

Austin, TX, USA

Brazilian radiopharmaceutical developer focused on peptide receptor radionuclide therapy (PRRT) for neuroendocrine and other cancers; developing locally produced Lu-177-DOTATATE and novel radioligand formulations for Latin American markets

Sao Paulo, Brazil

Clinical-stage radiotheranostics developer and AlphaMedix originator/co-developer

Houston, TX, USA

Fannin-founded company developing targeted radiopharmaceuticals using the proprietary Raptamer targeting platform for theranostic radioligand therapy; lead programmes target established and first-in-class cancer antigens; launched from stealth May 2024

Houston, TX, USA

Develops novel boron-containing inorganic nanoparticles for Boron Neutron Capture Therapy (BNCT) to overcome limitations of current BPA formulations

Kyoto, Japan

Discovers and develops small-molecule non-peptide radioligands targeting GPCRs overexpressed on solid tumors using a proprietary platform

San Diego, CA, USA

Novel-target radiopharmaceutical developer across PD-L1, HER2, B7-H3, KLK3 and brain-metastasis targets

Sydney, Australia

Dual proprietary platform: Trillium™ (trifunctional small-molecule scaffold for PK modulation) and Macropa™ (best-in-class bifunctional Ac-225 chelator)

Boston, MA, USA

Spinout from Telix/Heidelberg University Hospital developing a 99mTc/188Re-labelled PSMA-targeting theranostic pair (RHN001) leveraging generator-produced isotopes

Heidelberg, Germany

Large pharma entering Pb-212 pretargeted radioimmunotherapy

Basel / South San Francisco, Switzerland / USA

Large pharma licensee of lead-212 SSTR alpha therapy

Paris, France

Shanghai-based developer of [99mTc]SY101, a PSMA-targeted SPECT/CT diagnostic imaging agent for prostate cancer; CDE clinical trial approval December 2023; reported as the first domestic Tc-99m PSMA imaging agent in China with Phase III plans

Shanghai, China

China's leading theranostic radiopharmaceutical company with a broad pipeline; preclinical programs XTR015/XTR021/XTR024 alongside late-stage assets

Beijing, China

Builds a preclinical RPT pipeline in-licensing and developing Ac-225-based radiopharmaceuticals for solid tumors

Seoul, South Korea

Nanobody/single-domain antibody (SRC) platform for theranostic radiopharmaceuticals; therapeutic RDC programs in preclinical development

Suzhou, China

Developer and Phase 3 sponsor of [18F]FAPI-74, an FAP-targeted PET tracer for GI cancers; two Phase 3 trials active: FAPI-GO (gastroesophageal, first patient dosed Dec 2025) and FAPI-PRO (PDAC, first patient dosed Feb 2026); GE HealthCare licensing partner

Dulles, VA, USA

Antibody/nanobody-based radionuclide therapeutics incorporating Cereius (Duke University spinout, acq. 2023) modular site-specific radiolabeling

San Diego, CA / Durham, NC, USA

STO: SPAGO; develops 177Lu-SN201 (Tumorad), a receptor-independent nanoparticle radioligand therapy exploiting the EPR effect for tumour targeting; Phase I/IIa ongoing; also developing SpagoPix MRI contrast agent

Lund, Sweden

Israeli developer of somatostatin-based precision radioligands using an AI-driven peptide discovery platform; $18M Series A (Feb 2026); lead programme and breast/prostate cancer candidate entering clinical trials in Australia

Israel

ASX: SPL; develops DEP dendrimer-based radiotheranostics including a HER2 radiodiagnostic (89Zr) and radiotherapeutic (177Lu) programme; FDA-aligned first-in-human Phase 1 planned for H2 2026; primarily known for VivaGel and DEP drug delivery

Melbourne, Australia

Commercial-stage theranostic company with Phase 3 therapeutic programmes in prostate, brain and kidney cancers

Melbourne, Australia

Platform radiopharma biotech developing universal radiolabeling chemistry (tetrazine click ligation) for rapid theranostic radiopharmaceuticals

Copenhagen, Denmark

Radiotherapeutics subsidiary of Swiss Rockets developing Terbium-161-based radioligand therapies including 161Tb-PSMA for prostate cancer; discovery-stage programmes with academic and industrial partnerships; January 2026 deal with Alloy Therapeutics

Basel, Switzerland

Discovers and licenses next-generation radioligands for integrin-targeted theranostics, including an αvβ6-integrin therapeutic counterpart

Radeberg (near Dresden), Germany

Develops a modality-agnostic polyspecific integrin-binding peptide (PIP) tumor-targeting platform for drug conjugates, immunotherapy, and radioligand therapy

San Carlos, CA, USA

Designs BBB-crossing peptide/nanobody vectors (VECTrans®) for targeted delivery of radioisotopes to brain tumors and solid cancers

Marseille, France

Shandong-based developer of 177Lu-PSMA-VG01, a self-developed PSMA-targeted radioligand therapy for mCRPC; CDE IND accepted September 2025; also advancing preclinical 225Ac-PSMA-VG01 alpha programme

Shandong, China

Dedicated radiopharma subsidiary of Fosun Pharma developing pan-tumour theranostic radiopharmaceuticals; lead asset SRT-007 (Ga-68/Lu-177 PSMA theranostic pair) in Phase I for mCRPC; Fudan University patent collaboration covering solid-tumour targeted radioligands

Chengdu, China

Antibody therapeutics company that advanced I-131-omburtamab radioimmunotherapy in pediatric/rare cancers

New York, NY, USA

Chinese radiopharmaceutical manufacturer and parent of Lannacheng spin-out

Yantai, China

Major Chinese pharma (SZSE: 000538) with radiopharma pipeline through Yunhe Medicine subsidiary: INR101 (PSMA PET diagnostic, Phase III prostate cancer), INR102 (therapeutic RLT, Phase I/IIa), INR301 (mAb, IND accepted); PSMA-P137 patent licensed from Peking University Cancer Hospital

Kunming, China

Proprietary At-211 (astatine-211) platform with novel labeling/linker technology, integrated global isotope supply, and a pipeline of targeted alpha therapies

San Diego, CA, USA

Develops peptide-radionuclide conjugate (PRC) radioligand therapies; lead asset licensed to Novartis in January 2026 ($50M upfront, worldwide rights); internally developed RLT pipeline beyond the out-licensed programme; 200+ staff across Zhuzhou and New Jersey

Zhuzhou, China